JP2017521370A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017521370A5 JP2017521370A5 JP2016569613A JP2016569613A JP2017521370A5 JP 2017521370 A5 JP2017521370 A5 JP 2017521370A5 JP 2016569613 A JP2016569613 A JP 2016569613A JP 2016569613 A JP2016569613 A JP 2016569613A JP 2017521370 A5 JP2017521370 A5 JP 2017521370A5
- Authority
- JP
- Japan
- Prior art keywords
- concentration
- preparation according
- lyophilized
- nr2b9c
- tat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462004144P | 2014-05-28 | 2014-05-28 | |
| US62/004,144 | 2014-05-28 | ||
| PCT/IB2015/053996 WO2015181757A1 (en) | 2014-05-28 | 2015-05-28 | Lyophilized formulation of tat-nr2b9c with acetylation scavenger |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020087977A Division JP2020143116A (ja) | 2014-05-28 | 2020-05-20 | アセチル化スカベンジャーを含むＴａｔ−ＮＲ２Ｂ９ｃの凍結乾燥製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017521370A JP2017521370A (ja) | 2017-08-03 |
| JP2017521370A5 true JP2017521370A5 (enExample) | 2018-06-21 |
| JP6707469B2 JP6707469B2 (ja) | 2020-06-10 |
Family
ID=54698211
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016569613A Expired - Fee Related JP6707469B2 (ja) | 2014-05-28 | 2015-05-28 | アセチル化スカベンジャーを含むＴａｔ−ＮＲ２Ｂ９ｃの凍結乾燥製剤 |
| JP2020087977A Pending JP2020143116A (ja) | 2014-05-28 | 2020-05-20 | アセチル化スカベンジャーを含むＴａｔ−ＮＲ２Ｂ９ｃの凍結乾燥製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020087977A Pending JP2020143116A (ja) | 2014-05-28 | 2020-05-20 | アセチル化スカベンジャーを含むＴａｔ−ＮＲ２Ｂ９ｃの凍結乾燥製剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US10206878B2 (enExample) |
| EP (1) | EP3148568A4 (enExample) |
| JP (2) | JP6707469B2 (enExample) |
| CA (1) | CA2950392A1 (enExample) |
| WO (1) | WO2015181757A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10251935B2 (en) * | 2012-11-28 | 2019-04-09 | Nono Inc. | Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose |
| CA2950392A1 (en) | 2014-05-28 | 2015-12-03 | Nono Inc. | Lyophilized formulation of tat-nr2b9c with acetylation scavenger |
| UA123820C2 (uk) * | 2014-05-28 | 2021-06-09 | Ноно Інк. | Хлоридна сіль пептиду tat-nr2b9c |
| DK4553432T3 (da) | 2023-11-08 | 2026-06-29 | Bachem Holding Ag | Tørrepose og tørresystem |
| CN122122428A (zh) | 2023-11-08 | 2026-05-29 | 巴克姆股份公司 | 干燥袋和干燥系统 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009525986A (ja) * | 2006-02-03 | 2009-07-16 | メディミューン，エルエルシー | タンパク質製剤 |
| CA2647111A1 (en) * | 2006-03-28 | 2007-10-04 | F. Hoffmann-La Roche Ag | Anti-igf-1r human monoclonal antibody formulation |
| EP1884521A1 (en) * | 2006-07-31 | 2008-02-06 | Xigen S.A. | Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins |
| EP2196476A1 (en) * | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
| CN102413839A (zh) * | 2009-03-06 | 2012-04-11 | 医学免疫有限责任公司 | 人源化抗cd19抗体制剂 |
| WO2011017070A1 (en) | 2009-07-28 | 2011-02-10 | Merck Sharp & Dohme Corp. | Methods for producing high concentration lyophilized pharmaceutical formulations |
| PL3721904T3 (pl) * | 2009-11-20 | 2022-01-31 | Biocon Limited | Formulacje przeciwciała t1h |
| WO2011134979A2 (en) * | 2010-04-27 | 2011-11-03 | Scil Technology Gmbh | Stable mia/cd-rap formulation |
| US9629892B2 (en) | 2010-08-12 | 2017-04-25 | Nono Inc. | Treatment of penetrative injury to the brain |
| KR102374576B1 (ko) * | 2011-05-17 | 2022-03-15 | 솔리제닉스, 인크. | 열안정성 백신 조성물 및 그의 제조방법 |
| UY34105A (es) * | 2011-06-03 | 2012-07-31 | Lg Life Sciences Ltd | Formulación líquida estable de etanercept |
| US10251935B2 (en) | 2012-11-28 | 2019-04-09 | Nono Inc. | Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose |
| TR201905787T4 (tr) | 2012-11-28 | 2019-05-21 | Nono Inc | Liyofilize TAT-NR2B9C formülasyonu. |
| UA123820C2 (uk) | 2014-05-28 | 2021-06-09 | Ноно Інк. | Хлоридна сіль пептиду tat-nr2b9c |
| CA2950392A1 (en) | 2014-05-28 | 2015-12-03 | Nono Inc. | Lyophilized formulation of tat-nr2b9c with acetylation scavenger |
-
2015
- 2015-05-28 CA CA2950392A patent/CA2950392A1/en active Pending
- 2015-05-28 WO PCT/IB2015/053996 patent/WO2015181757A1/en not_active Ceased
- 2015-05-28 JP JP2016569613A patent/JP6707469B2/ja not_active Expired - Fee Related
- 2015-05-28 US US15/313,541 patent/US10206878B2/en active Active
- 2015-05-28 EP EP15800695.7A patent/EP3148568A4/en not_active Withdrawn
-
2019
- 2019-01-02 US US16/238,355 patent/US20190231693A1/en not_active Abandoned
-
2020
- 2020-05-20 JP JP2020087977A patent/JP2020143116A/ja active Pending
-
2021
- 2021-09-13 US US17/473,568 patent/US20220096383A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016150678A (ru) | ХЛОРИДНАЯ СОЛЬ ПЕПТИДА TAT-NR2B9с, КОМПОЗИЦИЯ НА ЕГО ОСНОВЕ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ | |
| JP2016520075A5 (enExample) | ||
| ZA201900367B (en) | Formulation of a peptide vaccine | |
| JP2015091902A5 (enExample) | ||
| BR112017009405A2 (pt) | composições antibióticas. | |
| WO2015044337A3 (en) | Dry formulations of vaccines that are room temperature stable | |
| PE20181400A1 (es) | Formulacion farmaceutica acuosa del anticuerpo anti-pd-l1 avelumab | |
| CL2011003003A1 (es) | Composicion tensioactiva reconstituida que comprende un polipeptido análogo a la proteína surfactante c nativa, un polipeptido análogo a la proteína surfactante b nativa, un fosfolipido monoinsaturado y un fosfolipido saturado, útil para el tratamiento del síndrome de dificultad respiratoria. | |
| JP2014000092A5 (enExample) | ||
| IN2012DE00337A (enExample) | ||
| PH12014501628B1 (en) | Stabilized formulations containing anti-ang2 antibodies | |
| WO2007035455A3 (en) | Stabilizers for freeze-dried vaccines | |
| AR080428A1 (es) | Formulaciones liquidas estabilizadas contentivas de anticuerpos | |
| WO2015020913A3 (en) | Influenza hemagglutinin proteins and methods of thereof | |
| HRP20191166T1 (hr) | Stabilizirani proteini, namijenjeni imuniziranju protiv bakterije staphylococcus aureus | |
| AR082257A1 (es) | Composicion de inmunoglobulinas humanas concentradas, procedimiento | |
| JP2017532343A5 (enExample) | ||
| PE20190110A1 (es) | Proteinas f de prefusion del vrs estabilizadas | |
| EA201491513A1 (ru) | Рекомбинантные штаммы escherichia coli | |
| UY37394A (es) | Métodos para alterar el contenido de aminoácidos en plantas | |
| HRP20211838T1 (hr) | Krnji protein vp4 rotavirusa i njegova primjena | |
| EA201991023A1 (ru) | Фармацевтическая композиция для парентерального введения, содержащая карглумовую кислоту | |
| RU2016111934A (ru) | Иммуногенные композиции коронавируса ближневосточного респираторного синдрома (mers-cov) и способы | |
| EA202092926A2 (ru) | Лиофилизированные составы, содержащие фактор ix | |
| EA202090536A1 (ru) | Кристаллические формы 3-замещенного 1,2,4-оксадиазола |